Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Depreciation and Depletion (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Depreciation and Depletion for 11 consecutive years, with $54000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion changed N/A to $54000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $56000.0, a N/A change, with the full-year FY2025 number at $84000.0, up 138.81% from a year prior.
  • Depreciation and Depletion was $54000.0 for Q4 2025 at Crescent Biopharma, up from -$12620.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $68088.0 in Q1 2021 to a low of -$12620.0 in Q2 2025.
  • A 5-year average of $45403.1 and a median of $47347.0 in 2022 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: rose 1.29% in 2021, then plummeted 66.65% in 2024.
  • Crescent Biopharma's Depreciation and Depletion stood at $61643.0 in 2021, then fell by 25.83% to $45718.0 in 2022, then plummeted by 49.04% to $23297.0 in 2023, then crashed by 37.25% to $14620.0 in 2024, then soared by 269.36% to $54000.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Depreciation and Depletion are $54000.0 (Q4 2025), -$12620.0 (Q2 2025), and $14620.0 (Q1 2024).